Marinus Pharmaceuticals announces NMPA approval of Ganaxolone for CDKL5 deficiency disorder
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a leader in developing innovative therapeutics for seizure disorders, has achieved a significant milestone with the approval of its ganaxolone oral ... Read More